Planning And Communication Are Key To Managing Distribution In COVID-19 Pandemic, Experts Say
Executive Summary
The pharmaceutical industry should use alternative transportation routes and have a business continuity plan for dealing with distribution center closures in light of the COVID-19 pandemic. They should also work closely with third-party logistics providers in ensuring drivers are complying PPE requirements.
You may also be interested in...
PhRMA And AAM Urge New Approaches In Dealing With COVID-19 Supply Chain Disruptions
As costs and delays mount, the brand and generic groups seek government solutions. AAM continues to press for federal contracts, and PhRMA wants the Department of Transportation to use its enforcement discretion under CARES Act to mandate international flights. AAM survey finds pandemic has caused 224% spike in the cost of transporting drugs.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.